Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimodipine plus cilostazol for prevention of vasospasm after aneurysmal subarachnoid hemorrhage
IRCT20221108056446N21Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimodipine and cilostazol in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Vasospasm. Started Dec 2025; status: completed.
02
Drugs
nimodipinecilostazol
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on IRCT20221108056446N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221108056446N21.